Abemaciclib in combination with endocrine therapy for the treatment of HR-positive/HER2-negative locally advanced/metastatic breast cancer in the UK: an observational study

Abstract Background Cyclin-dependent kinase 4/6 inhibitors combined with endocrine therapy are now standard of care in the first- or second-line settings for hormone receptor positive (HR+), human epidermal growth factor 2 negative (HER2-) patients with advanced / metastatic breast cancer (ABC/MBC)....

ver descrição completa

Detalhes bibliográficos

Principais autores:	Judy King, Walid Fakhouri, Rosalind Jarvis, Waleed Badreldin, Gavin Harper, Carlo Palmieri, Mark Nathan
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2025-07-01
coleção:	BMC Cancer
Assuntos:	Abemaciclib Medical chart review Metastatic breast cancer Observational Real-world Retrospective
Acesso em linha:	https://doi.org/10.1186/s12885-025-14526-w
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!